000303499 001__ 303499
000303499 005__ 20250829132522.0
000303499 0247_ $$2doi$$a10.1016/j.radonc.2025.111097
000303499 0247_ $$2pmid$$apmid:40803484
000303499 0247_ $$2ISSN$$a0167-8140
000303499 0247_ $$2ISSN$$a1879-0887
000303499 0247_ $$2altmetric$$aaltmetric:180215533
000303499 037__ $$aDKFZ-2025-01690
000303499 041__ $$aEnglish
000303499 082__ $$a610
000303499 1001_ $$aBlumenfeld, Philip$$b0
000303499 245__ $$aProspective clinical trial of upright image-guided proton therapy for locally recurrent head and neck and brain malignancies.
000303499 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000303499 3367_ $$2DRIVER$$aarticle
000303499 3367_ $$2DataCite$$aOutput Types/Journal article
000303499 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756466685_12782
000303499 3367_ $$2BibTeX$$aARTICLE
000303499 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303499 3367_ $$00$$2EndNote$$aJournal Article
000303499 500__ $$a#EA:E041# / Volume 211, October 2025, 111097
000303499 520__ $$aThe advent of commercially available vertical CT systems has renewed interest in gantry-less proton therapy (PT), in which patients are treated in an upright position using a fixed beamline and robotic positioning. This study evaluates the feasibility, safety, and preliminary efficacy of novel gantry-less image-guided adaptive PT (IGAPT) for recurrent head and neck (HN) and brain malignancies.A planned interim analysis was performed on 20 adult patients with recurrent HN (80 %) and brain (20 %) cancers, median age 62 years, with Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Patients underwent upright and supine imaging and simulation, followed by treatment planning comparing upright PT to conventional supine intensity-modulated radiotherapy (IMRT). Dosimetric analyses focused on organ-at-risk (OAR) sparing and target coverage. Toxicities were assessed prospectively every three months using the Common Terminology Criteria for Adverse Events (CTCAE).Gantry-less PT demonstrated significant dosimetric advantages over photon IMRT, including reduced doses to critical OARs including brainstem (6 Gy(RBE) vs. 19.1 Gy; p < 0.001) and spinal cord (12.5 Gy(RBE) vs. 18.3 Gy; p < 0.006). At 3-month follow-up (n = 14), a complete response was observed in 64.3 % of evaluable patients and a partial response in 21.4 %. Most toxicities were mild-to-moderate (grades 1-2), primarily dermatitis (55 %), fatigue (45 %), and mucositis (31.3 %). Grade 3 toxicities occurred in four patients (20 %). There were no device-related deaths.This first clinical evaluation of a novel gantry-less IGAPT system confirms its feasibility, safety, and promising efficacy for recurrent HN and brain cancer, with superior dosimetry and high local control rates. Its cost-effective design may improve global access to the IGAPT.
000303499 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000303499 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303499 650_7 $$2Other$$aAdaptive radiotherapy
000303499 650_7 $$2Other$$aImage guidance
000303499 650_7 $$2Other$$aProton therapy
000303499 650_7 $$2Other$$aRadiotherapy
000303499 650_7 $$2Other$$aUpright CT
000303499 650_7 $$2Other$$aUpright treatments
000303499 7001_ $$0P:(DE-He78)0704701d58e3a0d5f45fbd1018d5aa77$$aPryanichnikov, Alexander$$b1$$eFirst author$$udkfz
000303499 7001_ $$aHillman, Yair$$b2
000303499 7001_ $$aWajnryt, Ella$$b3
000303499 7001_ $$aBerger, Aviad$$b4
000303499 7001_ $$aWinograd, Shimshon$$b5
000303499 7001_ $$aWygoda, Marc$$b6
000303499 7001_ $$aSalhab, Ayman$$b7
000303499 7001_ $$aFang, Marcel$$b8
000303499 7001_ $$aFeldman, Jon$$b9
000303499 7001_ $$aPopovtzer, Aron$$b10
000303499 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2025.111097$$gp. 111097 -$$p111097$$tRadiotherapy and oncology$$v211$$x0167-8140$$y2025
000303499 909CO $$ooai:inrepo02.dkfz.de:303499$$pVDB
000303499 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0704701d58e3a0d5f45fbd1018d5aa77$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303499 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000303499 9141_ $$y2025
000303499 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-07$$wger
000303499 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2022$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000303499 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2022$$d2025-01-07
000303499 9201_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000303499 9200_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000303499 980__ $$ajournal
000303499 980__ $$aVDB
000303499 980__ $$aI:(DE-He78)E041-20160331
000303499 980__ $$aUNRESTRICTED